Navigation Links
A Statement from GlaxoSmithKline Consumer Healthcare on FDA Regulation of Smokeless Tobacco Products
Date:9/27/2010

PARSIPPANY, N.J., Sept. 27 /PRNewswire/ -- GlaxoSmithKline (GSK) Consumer Healthcare, a leader in helping smokers quit and the marketer of nicotine replacement therapy (NRT) products, including Nicorette® and NicoDerm® CQ®, supports the findings of the American Heart Association (AHA) policy statement regarding smokeless tobacco products.(1) GSK Consumer Healthcare agrees that these products should not be used as an alternative to cigarettes or for smoking cessation due to the potential negative health consequences and their impact on smoking behavior. 

The AHA statement is important because the U.S. Food and Drug Administration (FDA) has just finished accepting comments from the public on how FDA should regulate certain smokeless tobacco products.  GSK Consumer Healthcare submitted a comment to the FDA on the potential public health impact of oral dissolvable tobacco products.  In our submission, GSK Consumer Healthcare called for oral dissolvable tobacco products to be withdrawn from the market until their sponsors can demonstrate to FDA that their marketing is appropriate for the protection of public health.

The AHA policy statement, notes that smokeless tobacco products are not safe alternatives to smoking and are associated with heart attack, stroke and certain cancers.(1)  Also, due to the marketing of these products, smokeless tobacco products may also initiate further tobacco use and perpetuate smoking.(1) 

Tobacco use, including smokeless tobacco, is the largest cause of preventable death and disease in the world.(2)  More than 400,000 Americans die every year from tobacco-related disease.(2)  The only proven way to reduce these health consequences is to stop using tobacco completely.  Smokeless tobacco products are currently being marketed without clear evidence of their safety.

NRT products alternatively, have helped millions of people around the world quit smoking and, as a result, have significantly reduced their exposure to the risks of cancer and other smoking-related diseases.(3)  GlaxoSmithKline Consumer Healthcare believes that before considering a potential role for oral dissolvable tobacco products in reducing the adverse health effects of smoking, there are significant opportunities to enhance the impact of existing smoking cessation aids, including expanding access to and use of NRT products. While the FDA is the final authority on the labeling of NRT products sold in the U.S., GSK Consumer Healthcare is committed to continuing to work with medical and clinical experts, and the FDA, to ensure that consumers have the best possible chance to quit smoking.

Quitting smoking is the single most important step smokers can take to improve their health – and it's also one of the most difficult.  By developing innovative new products and support systems to improve the quit experience, and helping to make the products as accessible as possible, GSK Consumer Healthcare works to inspire and enable every smoker to quit for good.

  1. Piano, et al. Impact of Smokeless Tobacco Products on Cardiovascular Disease: Implications for Policy, Prevention, and Treatment. A Policy Statement From the American Heart Association. Circulation published online Sep 13, 2010. Available at http://circ.ahajournals.org/cgi/reprint/CIR.0b013e3181f432c3v1?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=smokeless+tobacco&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT.
  2. Centers for Disease Control and Prevention. Targeting Tobacco Use: The Nation's Leading Cause of Preventable Death. Available at http://www.cdc.gov/nccdphp/publications/aag/osh.htm.
  3. GSK data on file.


'/>"/>
SOURCE GlaxoSmithKline Consumer Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott Statement on the FDA Advisory Committee Recommendation on Sibutramine
2. Statement from CHPA on Todays FDA Advisory Committee Meeting on Dextromethorphan
3. Media Statement: Robert Moussa, President and CEO, Dilon Diagnostics
4. Statement from Eli Lilly and Company Regarding Approval Recommendation from FDA Advisory Committee for Expanding the Pain Indications for Cymbalta® to a Broader Pain Population
5. Horizon Pharma, Inc. Files Registration Statement for Proposed Initial Public Offering
6. NCPA Statement on CVS Caremark-Aetna Agreement
7. GlaxoSmithKline Statement in Response to FDA Advisory Committees Vote on Safety of Avandia® (rosiglitazone)
8. Dendreon Statement on CMS National Coverage Analysis
9. NORD Calls for Statement of Policy on Orphan Drug Development
10. Teva Admits to Making False Statements in US Gianvi™ Label and Agrees to Corrective Measures
11. Alexza Pharmaceuticals Files Shelf Registration Statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical ... innovative solutions for injectable drug administration, today shared the ... ID Adapter for improving the intradermal administration of polio ... Skin Vaccination Summit in May 2017 by Dr. ... Polio Department, World Health Organization (WHO), and recently published ...
(Date:10/4/2017)... 2017  According to the Centers for Disease Control and Prevention (CDC), ... PhysicianOne Urgent Care is helping communities across Massachusetts , ... by offering no-cost* flu shots through the end of the month. ... insurance regulations. ... get a flu shot is by the end of October, according to ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, the ... by Walgreens and pharmacy benefit manager Prime Therapeutics LLC ... brand, which included the unveiling of new signage at ... as well as at a few other company-owned facilities ... brand to patients, some of whom will begin to ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... cold therapy products, announced today the introduction of an innovative new design of the ... multipurpose pad so you get maximum comfort while controlling your pain while using cold ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
(Date:10/12/2017)... ... 2017 , ... Health Literacy Innovations (HLI), creator of the ... the Cancer Patient Education Network (CPEN), an independent professional organization that shares best ... alliance. , As CPEN’s strategic partner, HLI will help support CPEN members ...
Breaking Medicine News(10 mins):